Baseline characteristics of 34 patients with RA.
| N = 34 | |
|---|---|
| Age, yrs | 54 (10) |
| Female, n (%) | 27 (79) |
| Waist circumference, cm | 89 (16) |
| BMI, kg/m2 | 29 (6) |
| Systolic BP, mmHg | 114 (16) |
| Diastolic BP, mmHg | 70 (9) |
| Current smoking, n (%) | 7 (26) |
| Hypertension, n (%) | 8 (24) |
| Diabetes, n (%) | 3 (9) |
| Statin therapy, n (%) | 2 (6) |
| CRP, mg/L, median (IQR) | 2.98 (1.12-6.60) |
| RA-related characteristics | |
| Disease duration, yrs, median (IQR) | 9 (3-14) |
| RF, n (%) | 15 (44) |
| ACPA, n (%) | 24 (71) |
| DAS28-CRP | 3.72 (1.06) |
| CDAI, median (IQR) | 17 (9-26) |
| Tender joint count, median (IQR) | 6 (2-11) |
| Swollen joints, median (IQR) | 7 (3-12) |
| HAQ, median (IQR) | 1.11 (0.69-1.55) |
| NSAIDs, n (%) | 7 (21) |
| Prednisone, n (%) | 8 (24) |
| Methotrexate, n (%) | 26 (76) |
| Sulfasalazine, n (%) | 2 (6) |
| Hydroxychloroquine, n (%) | 4 (12) |
| Leflunomide, n (%) | 2 (6) |
| Biologic therapy, n (%) | 12 (35) |
| Anti-TNF therapy, n (%) | 7 (21) |
Values are expressed as mean (SD) unless otherwise indicated. ACPA: anticitrullinated protein antibody; BP: blood pressure; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints; HAQ: Health Assessment Questionnaire; NSAID: nonsteroidal antiinflammatory drug; RA: rheumatoid arthritis; RF: rheumatoid factor; TNF: tumor necrosis factor.